BioSpace News Archive

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Cannabotech (TASE: CNTC), a biotechnology company that developed OncoRix – an integrative oncology brand, based on Cannabis and functional mushroom extracts, published the results of its study using an ex-vivo model to test its anticancer efficacy on breast cancer tissues.

Ellipses Pharma, a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, announces a significant expansion of its Scientific Affairs Group.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be presenting at the upcoming Jefferies Radiopharma Innovation Summit.

Neuvivo today announced the publication of a peer-reviewed paper titled: “Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS”.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company which was held on March 29, 2023.

Decibel Therapeutics today announced that the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) has issued a positive opinion on orphan drug designation for DB-OTO, Decibel’s lead gene therapy product candidate designed to provide durable, high quality, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of the otoferlin gene.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS.

EIP Pharma Inc. and Diffusion Pharmaceuticals Inc., announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies.